{rfName}
In

Indexed in

License and Use

Icono OpenAccess

Altmetrics

Analysis of institutional authors

Rius-Rocabert, SergioAuthorPalacin-Aliana, IrinaAuthorNistal-Villan, EstanislaoCorresponding Author

Share

November 19, 2025
Publications
>
Article
Sí

Infectious bursal disease virus (IBDV) as a novel oncolytic virotherapy in glioblastoma

Publicated to: Journal for ImmunoTherapy of Cancer. 13 (11): e011741- - 2025-11-05 13(11), DOI: 10.1136/jitc-2025-011741

Authors:

Tur-Planells, V; Bykov, Y; Dawodu, G; García-Romero, N; Izpura-Luis, S; Pérez-Rodríguez, L; Rius-Rocabert, S; Palacín-Aliana, I; Arranz-Herrero, J; Márquez-Leiva, I; Monago-Sanchez, A; del Rio, ML; Rodriguez-Barbosa, JI; Cano-Ochando, J; García-Sastre, A; Lozano-Ojalvo, D; Nistal-Villan, E; Ayuso-Sacido, A; Cuadrado-Castano, S
[+]

Affiliations

- Author
CEU Univ, Univ San Pablo CEU, Fac Farm, Microbiol Sect,Dept Ciencias Farmaceut & Salud, Madrid, Spain - Author
CEU Univ, Univ San Pablo CEU, Inst Med Mol Aplicada Nemesio Diez IMMA ND, Dept Basic Med Sci,Fac Med,Inst Appl Mol Med IMMA, Madrid, Spain - Author
Ctr Invest ciencias alimentac CSIC UAM, CIAL, Madrid, Spain - Author
Grp Hosp Vithas, Fdn Vithas, Brain Tumour Lab, Madrid, Spain - Author
Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, New York, NY USA - Author
Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA - Author
Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY USA - Author
Icahn Sch Med Mt Sinai, Dept Pathol Mol & Cell Based Med, New York, NY 10029 USA - Author
Icahn Sch Med Mt Sinai, Global Hlth & Emerging Pathogens Inst, New York, NY USA - Author
Icahn Sch Med Mt Sinai, Icahn Genom Inst, New York, NY 10029 USA - Author
Icahn Sch Med Mt Sinai, Marc & Jennifer Lipschultz Precis Immunol Inst PrI, New York, NY 10029 USA - Author
Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA - Author
Inst Salud Carlos III, Natl Ctr Microbiol, Madrid, Spain - Author
Univ Francisco de Vitoria, Fac Expt Sci, Pozuelo De Alarcon, Spain - Author
Univ Francisco de Vitoria, Fac Med, Madrid, Spain - Author
Univ Leon, Lab Inmunobiol Trasplante Inmunoterapia, Inst Biol Mol INBI, Leon, Spain - Author
See more

Abstract

Background Glioblastoma (GBM) is the most aggressive form of cancer of the central nervous system. Despite advances in immunotherapies and standard-of-care treatments for GBMs, clinical outcomes remain limited-owing to the immunosuppressive tumor microenvironment and the intrinsic resistance of GBM to conventional approaches. As a result, there is growing interest in rational combination strategies, particularly those pairing oncolytic viruses with immune-based therapies or established treatment modalities. Oncolytic viruses, by displaying conditionally enabled tumor cell-restricted replication, while stimulating antitumor immune responses and leaving healthy tissue unharmed, have the potential to reshape the therapeutic landscape in GBM and aid in achieving more durable benefits for patients. This study investigates the use of infectious bursal disease virus (IBDV) as a potential virotherapy for GBM.Methods and results In vitro, IBDV infects and replicates within murine GBM cells and patient-derived GBM stem cells, inducing direct oncolysis and activating proinflammatory gene expression programs. IBDV also enhances the cytolytic activity of temozolomide (TMZ) in treated GBM cells, complementing TMZ chemotherapeutic activity. In vivo, treatment with IBDV in CT-2A GBM-bearing syngeneic mice significantly reduced tumor growth and improved survival compared with control mice. Intratumoral administration of IBDV induces a deep remodeling of the tumor immune microenvironment, reducing immunosuppressive M2-like macrophages and increasing the ratio of CD8+T cells to regulatory T cells. This reversion of immunosuppression linked to monocyte-derived macrophages has been confirmed on experimental ex vivo infections of explants derived from human GBM donors.Conclusion These findings support further consideration of IBDV as a novel virotherapeutic agent for GBM.
[+]

Keywords

AnimalsBrainBrain neoplasmsCell line, tumorCentral nervous system cancerCentral-nervous-systemComplexExpressionGlioblastomaGliomasHumansImmunotherapyInfectious bursal disease virusIntratumoralMacrophagesMiceOncolytic virotherapyOncolytic virusOncolytic virusesPathwayRegulatory t-cellsTemozolomideTumor microenvironmentTumor microenvironment - tmeTumorsXenograft model antitumor assays

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Journal for ImmunoTherapy of Cancer due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2025, it was in position 12/183, thus managing to position itself as a Q1 (Primer Cuartil), in the category Immunology. Notably, the journal is positioned above the 90th percentile.

[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-02:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 8.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 6 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 28.
  • The number of mentions on the social network X (formerly Twitter): 5 (Altmetric).
  • The number of mentions in news outlets: 3 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
[+]

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: United States of America.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Tur-Planells, Vicent) .

the author responsible for correspondence tasks has been NISTAL VILLAN, ESTANISLAO.

[+]

Awards linked to the item

This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project "PI21/01353" and co-funded by the European Union.
[+]